Crestone Awarded Funding by Cystic Fibrosis Foundation to Develop Antibiotic That Fights NTM Infections

Crestone Awarded Funding by Cystic Fibrosis Foundation to Develop Antibiotic That Fights NTM Infections

Crestone has received an award from the Cystic Fibrosis Foundation (CFF) to develop preclinical studies for an antibiotic to treat non-tuberculous mycobacteria (NTM) infections.

NTMs are responsible for lung infections in 14% of people with cystic fibrosis (CF).

The number of people affected by lung NTM infections is steadily increasing in the U.S., and patients with an existing chronic pulmonary condition like CF, bronchiectasis, or chronic obstructive pulmonary disease often are at increased risk.

Treating NTM infections can be difficult because the bacteria can become resistant to certain antibiotics (antimicrobial resistance), and alternative treatments may involve medications that are more toxic and cause adverse side effects. Mycobacterium abscessus (M. abscessus) in particular, is an NTM often difficult to treat.

“Potent antibiotics with a novel mode of action and a good safety profile are sorely needed to augment the armamentarium of NTM drugs” Mary Ann DeGroote, MD, who is involved in Crestone’s NTM discovery program, said in a press release.

Crestone’s program will investigate the use of compounds that can block the activity of MmpL3 (Mycobacterial membrane protein Large 3), a protein that is located on the NTM bacteria’s cell membrane and is essential for the bacteria to build their cell wall.

Crestone’s NTM treatment candidates will be tested at Colorado State University and Johns Hopkins University, using different pre-clinical models that mimic what happens in humans with a chronic NTM infection.

At National Jewish Health in Denver, researchers will study the more promising therapies further by testing how effective they are at killing M. abscessus bacteria isolated from patients with CF, and how the bacteria may be able to resist treatment.

“We are excited to advance our NTM program to the lead development stage where we plan to develop drug formulations for both oral and inhaled therapy. Our goal is to demonstrate a pharmacology, tolerability and efficacy profile that warrants the declaration of an IND [investigational new drug] candidate,” said Urs Ochsner, PhD, co-founder and vice president of research and development at Crestone.

The CFF Therapeutic Development Award will fund part of Crestone’s program for two years, but Crestone will have the opportunity to request further support to continue developing its pre-clinical and clinical studies of new therapeutic compounds, including dose and safety assessment studies in patients with CF.

The amount of the award was not disclosed.

Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Latest Posts
  • Respiratory Care
  • ELX-02 trials enrollment
  • mucus and bacteria
  • Staphylococcus aureus

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?